Data show mean ± standard deviation, mean [range], or number (%) | Cases | Controls |
---|---|---|
Number | 23 | 311 |
Age (years) | 52.2 ± 17.9 | 47.5 ± 14.2 |
Sex | ||
 Female | 15 (65.2%) | 148 (47.6%) |
 Male | 8 (34.8%) | 163 (52.4%) |
Rheumatic disease | ||
 Rheumatoid arthritis | 13 (56.5%) | 155 (49.8%) |
 Ankylosing spondylitis | 5 (21.7%) | 100 (32.2%) |
 Psoriatic arthritis/Psoriasis | 4 (17.4%) | 52 (16.7%) |
 Juvenile idiopathic arthritis | 1 (4.4%) | 4 (1.3%) |
Detectable HBV DNA (≥10 IU/ml) | 0 | 0 |
Anti-HBV core antigen positive | 15 (65.2%) | 189 (60.8%) |
Baseline serum anti-HBs titer (mIU/ml) | ||
 Mean [Min–Max] | 22.6 [10.1–64.7] | 284.5 [11.5–1000]a |
 ≤ 100 | 23 (100%) | 128 (41.2%) |
 > 100 | 0 | 183 (58.8%) |
Biologic DMARDs | ||
 Anti-TNF (Etanercept, Adalimumab, Golimumab) | 14 (60.9%) | 231 (74.3%) |
 Not anti-TNF | 9 (39.1%) | 80 (25.7%) |
  Abatacept | 1 (4.4%) | 11 (3.5%) |
  Rituximab | 1 (4.4%) | 11 (3.5%) |
  Tocilizumab | 2 (8.7%) | 12 (3.9%) |
  Tofacitinib | 3 (13.0%) | 19 (6.1%) |
  Ustekinumab | 2 (8.7%) | 25 (8.0%) |
  Secukinumab | 0 | 2 (0.6%) |
Conventional DMARDs (accumulated dose) | ||
 Methotrexate (mg) | 536 ± 869 | 537 ± 734 |
 Leflunomide (mg) | 748 ± 2083 | 707 ± 3021 |
 Sulfasalazine (g) | 350 ± 354 | 242 ± 318 |
 Hydroxychloroquine (g) | 67 ± 102 | 54 ± 100 |
 Cyclosporine (g) | 9 ± 22 | 8 ± 27 |
Prednisolone (accumulated dose, mg) | 2244 ± 2614 | 1422 ± 1910 |
Comorbidities | ||
 Prior alanine transaminase elevationb | 2 (8.7%) | 10 (3.2%) |
 Hepatitis C virus antibody positive | 2 (8.7%) | 11 (3.5%) |
 Diabetes mellitus | 4 (17.4%) | 12 (3.9%) |
 Chronic liver disease | 5 (21.7%) | 30 (9.7%) |
 Chronic kidney disease | 3 (13.0%) | 3 (1.0%) |